Orthocell has announced the successful completion of the first Remplir™ surgical case in Hong Kong and the official launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.
These achievements mark the start of clinical use and commercial sales in Hong Kong, following the appointment of MontsMed as exclusive in-country distributor. The launch event introduced Remplir to key opinion leaders and specialists in orthopaedic and reconstructive surgery, highlighting its clinical advantages in peripheral nerve repair.
Orthocell CEO and MD, Paul Anderson said:
“The completion of our first Remplir surgical case and successful launch at the Hong Kong Orthopaedic Association Annual Congress represent important progress in our deliberate and considered approach to commercialising Remplir across Asia.
Hong Kong’s advanced healthcare system and its role as a gateway to the Greater Bay Area present a compelling opportunity for expansion. We are pleased to be working with MontsMed to build awareness and drive adoption among leading surgeons.”